Rx-to-OTC: Unwanted Attention

Gopal,Kevin;

Article

Pharmaceutical Executive

June 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-06-01-2001

Volume0

Issue 0

Rx-to-OTC: Unwanted Attention

Author(s):

Kevin Gopal

Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.

Articles in this issue

Industry Under Investigation

Emotion - The New Brand Integrator

For Love of the Game

Field of Dreams

Workshop: Access Options

Emotion - The New Brand Integrator

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Rx-to-OTC: Unwanted Attention

Newsletter